foslevodopa/foscarbidopa vs Levodopa/carbidopa (ND0612)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Parkinson's Disease
Shared mechanism: dopamine precursor · full Parkinson's Disease pipeline
foslevodopa/foscarbidopa · Vyalev
Marketed by AbbVie
NCT04380142 · Phase 3 · completed
The trial randomized 145 participants to active treatment or an active comparator, with participants, clinicians, investigators, and outcome assessors quadruple-blinded. The primary clinical endpoint was met: least-squares mean improvement in “On” time was 2.72 hours with ABBV-951 versus 0.97 hours with oral carbidopa/levodopa, a difference of 1.75 hours (95% CI 0.46–3.05; p=0.0083).
Reported efficacy
Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia (Baseline (Week 0) up to Week 12 of the double-blind treatment period): ABBV-951 + Placebo for LD/CD 2.72 hours (Standard Error 0.52) vs LD/CD + Placebo for ABBV-951 0.97 hours (Standard Error 0.5) (met)
Result source: NCT04380142
Levodopa/carbidopa (ND0612) · Onerji
Marketed by NeuroDerm Ltd.
NCT02577523 · Phase 2 · completed
Participants were randomized to two ND0612 regimens, but the study was only single-blinded for outcome assessors, had no placebo or active-control arm, and was small with 19 participants per group. The clinical primary endpoint was daily OFF time; although the 24-hour regimen showed a numerically greater reduction, statistical significance for the comparison was not reported, so the result is unclear.
Reported efficacy
Change in Daily "OFF" Time (Baseline to Day 28): Change in Daily "OFF" Time (Baseline to Day 28): ND0612 Regimen 1 - 24-hr Infusion -2.8 Hours (95% CI -4.6--0.9) vs ND0612 Regimen 2 - 14-hr Infusion -1.3 Hours (95% CI -3.1-0.5) (unclear)
Result source: NCT02577523
Results for Parkinson's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | foslevodopa/foscarbidopa | Levodopa/carbidopa (ND0612) |
|---|---|---|
| OFF time, change | -2.8 vs -1.0vs LD/CDNCT04380142 | -2.1 vs -1.4−0.7 vs placeboNCT01883505 |
| ON time without troublesome dyskinesia, change | 2.7 vs 1.0vs LD/CDNCT04380142 | —Trial running · NCT04006210 |
| UPDRS Part III, change | —Not posted · NCT04379050 | —Trial running · NCT04006210 |
| MDS-UPDRS Part II, change | -2.6 vs -1.1vs LD/CDNCT04380142 | —Trial running · NCT04006210 |
OFF time, change
- foslevodopa/foscarbidopa
- -2.8 vs -1.0vs LD/CDNCT04380142
- Levodopa/carbidopa (ND0612)
- -2.1 vs -1.4−0.7 vs placeboNCT01883505
ON time without troublesome dyskinesia, change
- foslevodopa/foscarbidopa
- 2.7 vs 1.0vs LD/CDNCT04380142
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
UPDRS Part III, change
- foslevodopa/foscarbidopa
- —Not posted · NCT04379050
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
MDS-UPDRS Part II, change
- foslevodopa/foscarbidopa
- -2.6 vs -1.1vs LD/CDNCT04380142
- Levodopa/carbidopa (ND0612)
- —Trial running · NCT04006210
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. foslevodopa/foscarbidopa: 5 of 5 rows · Levodopa/carbidopa (ND0612): 4 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | foslevodopa/foscarbidopa Rows use multiple source trials | Levodopa/carbidopa (ND0612) Rows use multiple source trials |
|---|---|---|
| OFF Time absolute change · hours No placebo or comparator arm | -3.51 hours @ 52wka,b,c,d,e NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 show 2 more doses-3.59 hours @ 52wkhigh dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 -3.43 hours @ 52wklow dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | -2.8 hours @ 4wk24-hr Infusiona,b,c,d,e NCT02577523 · Phase 2 show 1 more dose-1.3 hours @ 4wk14-hr Infusion NCT02577523 · Phase 2 |
| Dropout rate | — NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results—ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 42.5%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 35.9%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | —24-hr Infusionf NCT02577523 · Phase 2 show 4 more results—14-hr Infusion NCT02577523 · Phase 2 0%Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination |
| Discontinued due to AEs | — NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results—ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 22.1%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 17.6%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | —24-hr Infusionf NCT02577523 · Phase 2 show 4 more results—14-hr Infusion NCT02577523 · Phase 2 —Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence —Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination |
| Serious AEs | 8.1% NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more results25.8%ABBV-951 All Participants NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 27.4%high dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 24.4%low dose NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 10.5%24-hr Infusionf NCT02577523 · Phase 2 show 4 more results10.5%14-hr Infusion NCT02577523 · Phase 2 5.3%Period 1. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence 0%Period 2. ND0612 NCT01883505 · Phase 2 · registry result, not featured evidence 0%Period 2. ND0612 + Entacapone NCT01883505 · Phase 2 · registry result, not featured evidence · combination |
| Most frequent reported AEs | infusion site erythema 27% infusion site pain 25.7% infusion site cellulitis 17.6% NCT04380142 · Phase 3 · Parkinson's Disease · phase 3 show 3 more resultsinfusion site erythema 52% infusion site nodule 28.7% infusion site oedema 19.3% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 high dose infusion site erythema 55.8% infusion site nodule 30.1% infusion site oedema 24.8% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 low dose infusion site erythema 48.9% infusion site nodule 27.5% infusion site cellulitis 19.1% NCT03781167 · Phase 3 · monotherapy · Parkinson's Disease · phase 3 | 24-hr Infusionf infusion site nodule 57.9% infusion site erythema 26.3% infusion site bruising 21.1% NCT02577523 · Phase 2 show 4 more results14-hr Infusion infusion site nodule 36.8% infusion site bruising 15.8% infusion site haemorrhage 15.8% NCT02577523 · Phase 2 fatigue 10.5% (placebo 0%) headache 10.5% (placebo 9.1%) abdominal pain lower 5.3% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence blood creatinine abnormal 12.5% (placebo 0%) dental caries 12.5% (placebo 0%) diarrhoea 12.5% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence back pain 12.5% (placebo 0%) pain in extremity 12.5% (placebo 9.1%) abdominal pain lower 0% (placebo 0%) NCT01883505 · Phase 2 · registry result, not featured evidence · combination |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2.
- cPopulation comparability has not been reviewed for both studies.
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 52 weeks versus 4 weeks.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
foslevodopa/foscarbidopa
show 17 more results
show 17 more results
show 29 more results
show 29 more results
show 29 more results
+ 4 further endpoints in the CSV export.
Levodopa/carbidopa (ND0612)
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: foslevodopa/foscarbidopa's landscape · Levodopa/carbidopa (ND0612)'s landscape